TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: AUC(0-last) - Total Systemic TPOXX Exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time To Maximum TPOXX Exposure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Proportion of participants with clinical success
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rSO2 values comparison
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Gaze position
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in active minutes of exercise
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Number of Biotin Labeled RBCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Half-life of Biotinylated RBCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Mean Potential Lifespan (MPL) of Biotinylated RBCs
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Clinically significant changes in physical and neurological examination findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Clinically significant changes in clinical laboratory outcomes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinically significant changes in 12-lead ECG findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Clinically significant changes in concomitant medications
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of life score (EORTC QLQ C30)
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of life score QLQ-HN35
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: composite satiety score (CSS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NEST scale total score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Incidence of LIFU-related adverse events as assessed by clinical MRI
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of LIFU-related adverse events as assessed by neurological examinations
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence of LIFU-related adverse events as assessed by neuropsychological testing
Endpoint domain: Adverse events/effects
Primary endpoint: Percentage of patients experiencing at least one adverse effect
Endpoint domain: Adverse events/effects
Primary endpoint: Sensitivity of Prostate Cancer Multimodal Model
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Specificity of Prostate Cancer Multimodal Model
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ROC value of Prostate Cancer Multimodal Model
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Incidence and severity of ocular treatment emergent adverse event (TEAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Incidence and severity of ocular treatment emergent serious adverse event (TESAEs)
Endpoint domain: Adverse events/effects
Primary endpoint: Number of participants with any clinically significant changes in vital signs
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Beta-hydroxybutyrate (BHB) Level
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Client satisfaction survey (CSQ-8)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overt Aggression Scale-Modified (OAS-M)
Endpoint domain: Adverse events/effects
Primary endpoint: Inventory of Interpersonal Problems-Short Version (IIP-32)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: State Trait Anger Expression Inventory-2 (STAXI-2)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Functional throwing performance index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Medicine ball throw test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Taste Alteration Severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Revised Memory and Behavior Problem Checklist Score
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Daily Peak Pruritus Numerical Rating Scale (NRS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Agitation assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Maximum tolerated dose/recommended phase 2 dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Seizure freedom of patients with hypermetabolism compared to those with hypometabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: Time of maximal fibrosis activity following myocardial infarction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fibrosis activity predicts myocardial scar volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Fibrosis activity and myocardial remodelling within atherosclerotic plaque
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Confirmed central nervous system ORR (CNS-cORR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Progression free survival (PFS) at 6 months post treatment initiation
Endpoint domain: Mortality/survival
Primary endpoint: Relapse free survival (RFS) at 6 months after surgery of metastases
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of Subjects With >=15 Letter Gain Without >=5 Letter Loss in Near Visual Acuity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time per Week Spent With Factor VIII (FVIII) Trough Level Below 1 Percent
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: AUC0-Infinity ratio of tacrolimus with cannabidiol vs tacrolimus alone
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number and frequency of Treatment-Emergent Adverse Events
Endpoint domain: Adverse events/effects
Primary endpoint: Proportion of Individuals Predicted to Develop High Myopia at Age 18
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cumulative Clinical Visit Rate for Myopia Prevention and Control
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Changes in Activities-Specific Balance Confidence Scale (ABC)
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Changes in Parkinson's Disease Fatigue Scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Incidence of AE/SAE
Endpoint domain: Adverse events/effects
Primary endpoint: Pneumonia improvement rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Diagnostic value of miRNAs as biomarkers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Liver affection
Endpoint domain: Physiological/clinical
Endpoint subdomain: Liver and biliary outcomes
Primary endpoint: Total weaning period
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: tpCR (BIRC, AJCC 8th)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Change From Baseline in RSV Viral Load Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Change From Baseline in RSV Viral Titer Measurements
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: WHO-5 Well-being Index
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Quality of Life Scale (QIDS)
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Positive rate of serum M protein
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: iHOT-12 score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Cognitive Dysfunction Evaluation - Digit Symbol Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive Dysfunction Evaluation - Number Combination Test-A
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive Dysfunction Evaluation - Number Combination Test-B
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive Dysfunction Evaluation - Serial Punctuation Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Cognitive Dysfunction Evaluation - Line Drawing Test
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: half maximum effective concentration (EC50) of remifentanil
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Computed Tomography Angiography results
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in Reaction Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Percentage of Correct Responses in Cognitive-Motor Running T-test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Completion Time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in Hop distance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Optic nerve and macular blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Hypoxic Burden (HB)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change from Baseline in Work Ability
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Relative alpha power
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Protein OX40 Expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of blood components transfused meeting alert criteria
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Addiction treatment engagement
Endpoint domain: Life impact
Endpoint subdomain: Role functioning
Primary endpoint: Duration of air leakage until sealed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Duration until chest drain removal
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Change in Activated Partial Thromboplastin Time (APTT) > 1.5 Seconds
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Number of Participants With a Negative Viral Load in Nasal Swab Reverse Transcription Polymerase Chain Reaction (RT-PCR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: IgG titers specific to Bordetella Pertussis Antigens
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Number of completed scoops in 24-Hour Retention Test
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knee Osteoarthritis Outcome Score (KOOS) change
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Peak knee adduction moment impulse change
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes of in-hospital days
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Freedom from Sensor Complications
Endpoint domain: Adverse events/effects
Primary endpoint: Retention and adherence rates
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Treatment dropout percentage
Endpoint domain: Adverse events/effects
Primary endpoint: Insulin autoimmune antibody levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Adverse Events ≥Grade 3
Endpoint domain: Adverse events/effects
Primary endpoint: Score on IWQOL-Lite
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Change in impulse oscillometry
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Proportion of superficial surgical site infections (SSI)
Endpoint domain: Adverse events/effects
Primary endpoint: Accrual and Retention Rate
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Modified Tardieu Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mismatch negativity (MMN) amplitude
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mismatch negativity (MMN) incubation period
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Proportion of adolescents who self-reported HIV testing and counseling (inclusive of Adolescent Wellness Visit)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Proportion of adolescents who self-reported HIV testing and counseling (exclusive of Adolescent Wellness Visit)
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Distant office control score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: airway microbial profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: airway inflammatory profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: airway mucin profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Food addiction
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prevalence of elevated Lipoprotein(a)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Change in liver fat measured using MRI
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in liver fibrosis (FIB-4 score)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: breast cancer disease-free interval
Endpoint domain: Mortality/survival
Primary endpoint: Objective mean wearing time
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Patient adherence with current monitoring recommendations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MiRNA expression correlation with MRI findings
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: 100 Percent Epithelialization (Closure) of Wound in Diabetic Foot Ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: 100 Percent Epithelialization (Closure) of Wound in Venous Leg Ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Overall Complete Hematologic Response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Clinical measurement of soft tissue thickness
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Value of HbA1c and HOMA-IR hormone
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Serum ADAM 17 and Caspase 3 levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: Incidence of adverse events and clinical laboratory abnormalities defined as dose-limiting toxicities (DLTs)
Endpoint domain: Adverse events/effects
Primary endpoint: LDL-cholesterolemia reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Clinical partial response (PR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical stable disease (SD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical disease progression (PD)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Protection against Coronary artery disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Generalized Anxiety Disorder Assessment
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Satisfaction With Genital Appearance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Quality of Sexual Life
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Visual Infusion Phlebitis Assessment Scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pediatric peripheral intravenous infiltration assessment tool
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of disagreements
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Percent of cisgender females persistent on CAB-LA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Change in angina symptom severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Pain Visual Analogic Scale
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Overall Quality of Vision Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Overall Quality of Comfort Score
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Geometric mean titer (GMT) of specific neutralizing antibody
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Seroconversion rate of serum anti-SARS-CoV-2 neutralizing antibody titers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: End-of-Life Care Knowledge Test
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Attitudes and Behaviors of Intensive Care Nurses Towards End-of-Life Care Scale
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Bioavailability of inhaled levosimendan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time-to-peak of inhaled levosimendan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Elimination half-life of inhaled levosimendan
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Final sum score of cardiovascular risk profile
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Seroprevalence of IgG against SARS-CoV-2
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Longevity of IgG response
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Sodium level disorders
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Changes in Daily Sleepiness
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Changes in Levels of Fatigue
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: Changes in Quality of Sleep
Endpoint domain: Life impact
Endpoint subdomain: Sleep
Primary endpoint: Longevity of correction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Richmond Sedation-Agitation Scale (RASS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Confusion Assessment Method in the Intensive Care Unit (Cam-ICU)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Child Anxiety Scale-State (CAS-S)
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Simpson index
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Microbiome composition by metagenomic analysis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NXT system performance
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: NXT system safety
Endpoint domain: Adverse events/effects
Primary endpoint: Nighttime oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Periodic Breathing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Difference in SBP change
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Reduction in unnecessary prostate biopsies
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pectoralis minor length
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Pectoralis minor tightness test I
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Safety: Adverse events, readmissions and mortality
Endpoint domain: Adverse events/effects
Primary endpoint: MMP-9 Expression in Epithelial Cells of Bulbar Conjunctiva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: MMP-9 Expression in Epithelial Cells of Upper Eyelid Wiper
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CLDEQ-8 Score follow up 1
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: CLDEQ-8 Score follow up 2
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: CHOD risk scale value
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Percentage of Participants Achieving EASI 90 and WPNRS 0/1
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Plaque Assessment
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Optic nerve head and macula perfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes